RheumNow’s expanded coverage of the #ACR22 Annual meeting is sponsored in part by Bristol-Myers Squibb. All content chosen by RheumNow & its Faculty

#ACR22 Abstr#0127. Cross-sectional study of 59 patients with #SAPHO and Chronic Nonbacterial Osteomyelitis showed that patients had high level of pain and fatigue and low function. Important to assess for these and could be a treatment target @RheumNow https://t.co/451KrlJWZF

mTORC1 may be driver of inflammation that connects the pathogenesis of sJIA and MAS as seen in mouse models. Further evaluation needs to be determined in humans, but interesting nonetheless. Abs 0004 #ACR22 @RheumNow https://t.co/RFokZqFQZp https://t.co/E7yxCPDGCd

• mTORC1 Drives the Spectrum of Pathology in Systemic JIA and Macrophage Activati…

🪞MIRROR RCT🪞 💊MTX ⬆️ response of Pegloticase in resistant gout pts (60% vs PBO 30.8%) 🦶Tophus resolution wk 52 >24 (cont. benefit💪🏻) 🧪⬇️ drug Ab with MTX ✅ No new IRs Abst#0001 #ACR22 @RheumNow #plenary https://t.co/8lPKQ0VGqC

Excellent start to the first plenary session! MIRROR study - MTX coadministration with pegloticase for gout treatment - doubling of efficacy and 7x decrease in infusion reactions - less anti-PEG abs @RheumNow #ACR22 Abs#0001 https://t.co/V1HIYypmpO

2022 IIM-assoc'd CA screening key takeaways Most common CA: lung, ovarian, colorectal, lymphoma, breast, & naso-pharyngeal High risk: DM, +anti-TIF1 gamma, +antiNXP2, >40 at IIM dx, severe/active dz, cutaneous necrosis, dysphagia Abs 0002 #ACR22 @RheumNow https://t.co/BhF1jJa8Oz https://t.co/oLVTLG34ck

• Cancer Screening Recommendations for Patients with Idiopathic Inflammatory Myop…

So good to be back in the plenary hall. It’s on #ACR22 @RheumNow https://t.co/0ppQy5CA3m

Best Overall! by Dr. Lauren Harper #ACR22 Image Competition @rheumnow https://t.co/D3bKJTx6ir

Keynote lecture from Abraham Varghese at #ACR22 @RheumNow Opening Session Physicians and Patients ◦ Physical examination is meaningful and cannot be replaced by technology ◦ Don’t treat the EHR, treat the patient ◦ Acknowledge how much goes into patient care by our nurses https://t.co/piV0O8O7Hw

@MayoClinic data for bari in relapsing GCA caused waves at #ACR21 Spanish data looking at real-world practice: slightly longer, slower GCA, but equally encouraging outcomes waiting for SELECT-GCA with interest! @EBRheum ABST0464 #ACR22 @RheumNow https://t.co/pVRPXAohhc https://t.co/FgNNfPSWk3

• https://twitter.com/drdavidliew/status/1457688108338606083

Ab0349 #ACR22 BEL vs AZA ifn risks in non-renal SLE BEL: lower risk of severe ifn (HR 0.81) and hospitalization for ifn (HR 0.73) through 5 yrs Challenge to interpret data as 56% of patients were on glucocorticoids and other anti-rheumatic meds @RheumNow https://t.co/a0tNFn5Wqr

⬆️ correlation between BASDAI + ASQoL in 🙋‍♂️ vs 🙋‍♀️ What does this mean? ❓low disease activity in 🙋‍♀️ resulting in more marked ⬇️ in QoL❓ OR ❓Is there a need for gender stratified tools of disease activity❓ Abst#0406 #ACR22 @RheumNow @Sineadm15

A #myositis discussion will not be complete without a slide on myositis antibodies - @JuliePaikMD Great review slide for trainees! #ACR22 @Rheumnow #RheumTwitter @rheumarhyme @PhRheumaJr @doktora_ging https://t.co/e6cB344vH8

MIRROR results showed 12-month safety/efficacy support MTX co-therapy w/ pegloticase. No IRs after 6mo of tx and increased resolution of tophi at wk 52. I use MTX in my gout pts on Pegloticase. Are you #rheumtwitter? Abs 0001 #ACR22 @RheumNow https://t.co/FLwOmAYrS4

• 12-month Findings of the Randomized, Double-Blind, Placebo-Controlled, Multicen…